For example, in uterine leiomyosarcoma, alterations affecting HRD may confer sensitivity to PARP inhibition [46], while MMR-deficient tumors may respond to immune checkpoint blockade [45,46]. The gene discussed is MRC1; the disease is leiomyosarcoma.